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Background: We evaluated the impact of paclitaxel coated balloon angioplasty (addressing neointimal proliferation) plus endothelial progenitor 
cell capturing (EPC) stent implantation (facilitating endothelialization) in de-novo lesions (NCT00732953).
Methods: In this prospective, single-blind, multicenter, trial we randomly assigned 120 patients with a de-novo lesions to undergo treatment either 
with paclitaxel coated balloon (SeQuent Please, BBraun, Melsungen) plus EPC stent (OrbusNeich) or EPC stent alone. Primary endpoint was in-stent 
late lumen loss at 6 months. Secondary clinical endpoint was composited of cardiac death, myocardial infarction attributed to the target vessel or 
TLR.
Results: Baseline and procedural data did not differ. Stented length was 16.4±6.5mm for DCB plus EPC and 17.5±6.4mm for EPC alone (p=0.32). 
Length of DCB segment was 20.2±7.6mm. Post PCI, for the stented segment and the total segment minimal lumen diameter and diameter stenosis 
were not different. Clinical follow-up after 12 months was 100%. Treatment with DCB plus EPC stent was superior to EPC stent alone with an in-stent 
late loss of 0.34±0.45mm vs. 0.88±0.48mm (p<0.001). Minimal lumen diameter was significantly larger and percent diameter stenosis significantly 
lower with use of the DCB for both the stented and total segment. Restenosis rate was reduced from 23.2% to 5.1% (P=0.005) and the clinical 
endpoint at 6 months was reduced from 17.2% to 4.8% (P=0.03), respectively. After 12 months the effect of DCB persisted (clinical endpoint 19.0% 
vs. 8.1%; p=0.08 and TLR 17.2% vs. 8.1%, p=0.13), respectively. There was no definite or probable stent thrombosis. Clinical follow-up after 2 years 
will be completed in March 2012 and presented.
Conclusions: Paclitaxel coated balloon plus EPC stent implantation was superior to EPC stent implantation alone for treatment of de-novo 
coronary artery disease. In both groups no stent thrombosis was observed. 
